Streetbeat News

ANEB

Anebulo Pharmaceuticals, Inc.

https://www.anebulo.com

Industry

Biotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Open

1.45

Mkt cap

36M

Volume

17K

High

1.50

P/E Ratio

-4.67

52-wk high

3.30

Low

1.39

Div yield

N/A

52-wk low

1.25

Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 11:54 am

Anebulo Pharmaceuticals reported a Q4 EPS loss of $(0.05), an improvement from the $(0.10) loss per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:06 pm

Anebulo Pharmaceuticals has received a $1.9 million grant from the National Institute on Drug Abuse (NIDA) for its investigational IV treatment of cannabis toxic effects. The grant will be disbursed in two tranches, with the initial $0.9 million awarded and the remaining $1 million contingent on meeting certain milestones.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 11:05 am

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Venus Concept (VERO), Asensus Surgical (ASXC), American Oncology Network (AONC), Anebulo Pharmaceuticals (ANEB), IN8bio (INAB), and Geron (GERN). On the losing side, Biomea Fusion (BMEA), Scinai Immunotherapeutics (SCNI), Seres Therapeutics (MCRB), Concord Medical Services (CCM), Arcturus Therapeutics (ARCT), and ENDRA Life Sciences (NDRA) saw declines.

Portfolio Pulse from Benzinga Insights

June 07, 2024 | 4:31 pm

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Novo Integrated Sciences (NVOS), Anebulo Pharmaceuticals (ANEB), Annovis Bio (ANVS), Vaccinex (VCNX), Genprex (GNPX), and Purple Biotech (PPBT). Significant losers include Calidi Biotherapeutics (CLDI), Summit Therapeutics (SMMT), Heart Test Laboratories (HSCS), Humacyte (HUMA), Concord Medical Services (CCM), and Pulse Biosciences (PLSE).

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 4:31 pm

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported a Q3 EPS loss of $(0.06), beating the analyst consensus estimate of $(0.12) by 50%. This represents a 45.45% improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:07 pm

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported a narrowed net loss for Q2 2024 and progress on its drug for acute cannabinoid intoxication (ACI), selonabant. The company's Q2 net loss was $2.7 million, down from $3.8 million in the same period last year, with total operating expenses decreasing to $2.8 million from $3.8 million. Anebulo received positive feedback from the FDA on its ANEB-001 drug for ACI, indicating a potential path for a new drug application. Shares of Anebulo traded 4.8780% higher at $2.58 per share following the announcement.

Portfolio Pulse from Jelena Martinovic

February 14, 2024 | 4:37 pm

Anebulo Pharmaceuticals has announced the appointment of Richie Cunningham as its new Chief Executive Officer. This leadership change is expected to bring new strategies and potentially positive shifts in the company's direction.

Portfolio Pulse from Happy Mohamed

February 13, 2024 | 9:44 pm

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported Q2 EPS of $(0.11), missing the consensus estimate of $(0.10) by 10%. This represents a 26.67% improvement over the $(0.15) per share loss from the same quarter last year.

Portfolio Pulse from Happy Mohamed

February 13, 2024 | 9:44 pm

Anebulo Pharmaceuticals has filed a U.S. patent application (No. 20240010617) for crystalline forms of a CB1 modulator, including methods of use and preparation. The patent application could potentially protect the company's intellectual property and strengthen its position in the market for cannabinoid receptor type 1 modulators.

Portfolio Pulse from Charles Gross

January 11, 2024 | 11:42 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.